Andexanet Alfa (Andexxa) Formulary Review

Volume: 18, Issue: 2, Pages: 66 - 71
Published: Jun 1, 2019
Abstract
Andexanet alfa, a recombinant modified human “decoy” factor Xa (FXa) protein, is the first and only available antidote approved by the Food and Drug Administration to manage life-threatening or uncontrolled bleeding associated with the anti-Xa agents. It binds to direct and indirect anti-Xa oral anticoagulants with high specificity to reverse their inhibitory effects and restore the activity of FXa. Andexanet alfa is administered via two...
Paper Details
Title
Andexanet Alfa (Andexxa) Formulary Review
Published Date
Jun 1, 2019
Volume
18
Issue
2
Pages
66 - 71
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.